Fischer Medical Ventures Limited (FISCHER | 524743 | INE771F01041), one of the leading companies engaged in the processing, manufacturing, and trading of laboratory-grade chemicals, has reported its financial results for FY26.
Key Business Highlights for FY26
Launch of new X-Ray Projects in India and Indonesia
Partnered City of Jember to deploy AI-powered portable X-ray systems. Supports “TB Free Jember by 2026” & TB elimination by 2030 projects valued at USD 10 million (approx.)
Secured full licensing in Indonesia, eligible to participate in End-TB Handheld X-ray Government Tender
Award of order by the Tamil Nadu Animal Husbandry Department for supply and installation of 65 Digital Radiography Units
Expansion in Philippines Markets
Province of Bulacan inaugurated the country’s first locally funded MRI facility developed by Time Medical
Diagnostic Imaging Expansion in India
Launched High-Resolution Open MRI at Sunray Scans, Chennai
Installed PICA 0.35T Open MRI at STNM Hospital, Sikkim
Launch of New Low-Field TOF MRI Platform MRI, VEGA specifically for brain aneurysm
Successful launch of next-generation 1.5T MRI platforms – MICA
Commenting on the Results, Mr. Ravindran Govindan, Chairman of Fischer Medical Ventures Limited, said:
“FY26 was a very strong year for Fischer, marking significant improvement across all operational and financial parameters. The steep rise in profitability reflects the scalability of our model, better product realization, and the growing acceptance of Fischer’s technology across India and overseas markets.
India’s MedTech and diagnostic industry is expanding rapidly, driven by government focus on indigenous manufacturing, preventive care, and AI-led healthcare solutions. Fischer is well aligned with these trends, leveraging its expertise in MRI systems, AI diagnostics, and digital health platforms to strengthen its position in this evolving landscape.
With our expanding footprint across Southeast Asia, new product launches, and advanced solutions such, we are confident of sustaining this growth momentum and creating long-term value for all”
Additional Developments
DRIS-iMRI Medharanya development in partnership with Dr. Iype Cherian for inter-operative MRI imaging
Recognition as Industry Partner of WFNS Innovation and Technological Committee (first industry partner in WFNS history)
Nanomedic regulatory progress: Phase 1 MDR/MDD audit completed; Phase 2 due Oct 2025; SpinCare® FDA filing expected Q2 FY27
Participation and partnerships at IRIA 2026 with QUIN
Key Consolidated Financial Highlights
| Particulars (₹ Cr) | FY26 | FY25 | YoY | H1 FY26 | H1 FY25 | YoY |
| Revenue | 30,857.56 | 11,069.87 | 179% | 19,882.56 | 6,092.27 | 226% |
| Total Income | 32,088.93 | 11,219.07 | 186% | 20,119.15 | 6,144.945 | 227% |
| EBITDA | 5,539.71 | 480.88 | 1052% | 2,493.40 | 352.605 | 607% |
| EBITDA margin | 17.3% | 4.3% | 1300 BPS | 12.4% | 5.7% | 670 BPS |
| Net Profit | 3,107.38 | 120.02 | 2489% | 1,210.64 | 101.04 | 1098% |
| Net Profit % | 9.7% | 1.1% | 860 BPS | 6.0% | 1.6% | 440 BPS |
| EPS (Diluted) | 0.45 | 0.02 | 2144% | 0.17 | 0.011 | 1433% |
Fischer Medical Ventures Limited (FMVL, the “Company”), Headquartered in Andhra Pradesh, with a facility at the Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, its subsidiary Time Medical International Ventures (India) Private Limited (TMIVPL) is the first Indian company recognized by CDSCO for indigenously manufacturing MRI systems. FMVL focuses on medical diagnostics, digital health, and AI-powered healthcare software. Its product range includes MRI systems (0.35T & 1.5T), preventive health kiosks, e-health access points (E-HAPs), AI-based software for cancer and TB screening, handheld X-ray devices, SpinCare technology, nutraceuticals from plant extracts, and contactless mental health screening. Upcoming products include oncology and CT scan solutions.FMVL aims to make healthcare accessible and affordable through innovation and data-driven solutions. Its 100% subsidiary FlynnCare Health Innovations Pvt. Ltd. provides digital platforms for community health screening and hospital connectivity.
